In post 9 of the series, we explained our methods for identifying PK data.
and in the following posts, 9a to 9e
we explained that the PK data seen by regulators lacked numbers and details, for example, with a lack of genotoxicity and carcinogenicity studies. In post 9b, we reported our understanding of the production of the misreported mRNA (alias mmRNA)
…
Keep reading with a 7-day free trial
Subscribe to Trust the Evidence to keep reading this post and get 7 days of free access to the full post archives.